Abstract
Viruses possessing class I fusion proteins require proteolytic activation by host cell proteases to mediate fusion with the host cell membrane. The mammalian SPINT2 gene encodes a protease inhibitor that targets trypsin-like serine proteases. Here we show the protease inhibitor, SPINT2, restricts cleavage-activation efficiently for a range of influenza viruses and for human metapneumovirus (HMPV). SPINT2 treatment resulted in the cleavage and fusion inhibition of full-length influenza A/CA/04/09 (H1N1) HA, A/Aichi/68 (H3N2) HA, A/Shanghai/2/2013 (H7N9) HA and HMPV F when activated by trypsin, recombinant matriptase or KLK5. We also demonstrate that SPINT2 was able to reduce viral growth of influenza A/CA/04/09 H1N1 and A/X31 H3N2 in cell culture by inhibiting matriptase or TMPRSS2. Moreover, inhibition efficacy did not differ whether SPINT2 was added at the time of infection or 24 h post-infection. Our data suggest that the SPINT2 inhibitor has a strong potential to serve as a novel broad-spectrum antiviral.
Original language | English |
---|---|
Pages (from-to) | 43-53 |
Number of pages | 11 |
Journal | Virology |
Volume | 543 |
DOIs | |
State | Published - Apr 2020 |
Bibliographical note
Publisher Copyright:© 2020 Elsevier Inc.
Keywords
- Antiviral therapy
- HAI-2
- HMPV
- HMPV F
- Hemagglutinin
- Influenza
- Proteases
- SPINT2
ASJC Scopus subject areas
- Virology